EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSHCOG00000014239
Gene Symbol: KCNH2
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSHCOG00000004440
Gene Symbol: LOC109511836
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSHCOG00000015144
Gene Symbol: KCNQ2
4 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSHCOG00000011878
Gene Symbol: KCNQ3
3 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSHCOG00000014664
Gene Symbol: KCNQ5
3 Cross references
196 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSHCOG00000011616
Gene Symbol: PSEN2
3 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSHCOG00000007239
Gene Symbol: PSENEN
3 Cross references
183 Possible Orthologues:

Presenilin-1-Like

Ensembl ID : ENSHCOG00000018868
Gene Symbol: LOC109517281
3 Cross references
200 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSHCOG00000003352
Gene Symbol: LOC109514575
3 Cross references
250 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSHCOG00000012753
Gene Symbol: LOC109520795
4 Cross references
255 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSHCOG00000012226
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Progesterone Receptor-Like

Ensembl ID : ENSHCOG00000003679
Gene Symbol: LOC109524475
2 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).